TickerFactsScreenerDevelopers

CRISPR Therapeutics AG (CRSP) — Cash & Equivalents

Annual figures by fiscal year, from SEC filings.

2013: $361.0K2014: $945.0K2015: $155.96M2016: $315.52M2017: $239.76M2018: $456.65M2019: $943.77M2020: $1.17B2021: $923.03M2022: $211.88M2023: $389.48M2024: $298.26M2025: $347.56M$347.56M
2013Cash & Equivalents (USD)2025
Fiscal YearCash & EquivalentsChange YoY
2025$347.56M+16.5%
2024$298.26M-23.4%
2023$389.48M+83.8%
2022$211.88M-77.0%
2021$923.03M-21.0%
2020$1.17B+23.8%
2019$943.77M+106.7%
2018$456.65M+90.5%
2017$239.76M-24.0%
2016$315.52M+102.3%
2015$155.96M+16403.8%
2014$945.0K+161.8%
2013$361.0K—